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The purpose of the current study was to test the hypothesis that the dipeptidyl peptidase IV (DPPIV)
inhibitor sitagliptin, which exerts anti-hyperglycemic and anti-hypertensive effects, upregulates GLUT4
translocation, protein levels, and/or mRNA expression in heart and skeletal muscle of spontaneously
hypertensive rats (SHRs). Ten days of treatment with sitagliptin (40 mg/kg twice daily) decreased
plasma DPPIV activity in both young (Y, 5-week-old) and adult (A, 20-week-old) SHRs to similar
extents (85%). However, DPPIV inhibition only lowered blood pressure in Y-SHRs (11973 vs.
13674 mmHg). GLUT4 translocation, total protein levels and mRNA expression were decreased in
the heart, soleus and gastrocnemius muscle of SHRs compared to age-matched Wistar Kyoto (WKY)
normotensive rats. These differences were much more pronounced between A-SHRs and A-WKY rats
than between Y-SHRs and Y-WKY rats. In Y-SHRs, sitagliptin normalized GLUT4 expression in the heart,
soleus and gastrocnemius. In A-SHRs, sitagliptin increased GLUT4 expression to levels that were even
higher than those of A-WKY rats. Sitagliptin enhanced the circulating levels of the DPPIV substrate
glucagon-like peptide-1 (GLP-1) in SHRs. In addition, stimulation of the GLP-1 receptor in cardiomyo-
cytes isolated from SHRs increased the protein level of GLUT4 by 154713%. Collectively, these results
indicate that DPPIV inhibition upregulates GLUT4 in heart and skeletal muscle of SHRs. The underlying
mechanism of sitagliptin-induced upregulation of GLUT4 in SHRs may be, at least partially, attributed
to GLP-1 .
& 2012 Elsevier B.V. Open access under the Elsevier OA license. 1. Introduction
Maintenance of glucose homeostasis relies both on insulin
secretion and insulin stimulation of facilitative glucose uptake,
which, in mammalian cells, is mediated by a family of glucose
transport proteins. In striated muscle (skeletal and cardiac) and
adipose tissues, this effect is primarily due to the recruitment of
glucose transporter type 4 (GLUT4) from intracellular vesicles to
the plasma membrane (James et al., 1988).
Abnormalities in glucose homeostasis have been observed in
hypertensive patients and in experimental models of hyperten-
sion. Numerous reports have documented that spontaneously
hypertensive rats (SHRs) exhibit changes in GLUT4 function,
trafﬁcking, and/or expression in insulin-sensitive tissues
(Campbell et al., 1995; Chiappe De Cingolani and Caldiz, 2004;143; fax: þ55 11 2661 5022.
C. Girardi).
ier OA license. Katayama et al., 1997; Lehnen et al., 2011; Paternostro et al.,
1995; Reaven et al., 1989). More speciﬁcally, most of these studies
have found that GLUT4 is downregulated in adipocytes, skeletal
and cardiac muscles from hypertensive animals.
Inhibitors of the enzyme dipeptidyl peptidase IV (DPPIV)
represent a novel class of anti-hyperglycemic agents that improve
the control of blood glucose levels in type 2 diabetic patients
primarily by preventing the DPPIV-mediated rapid degradation of
the incretin glucagon-like peptide-1 (GLP-1) (Ahren, 2003;
Drucker, 2003; Drucker and Nauck, 2006; Holst, 2007). Notably,
studies of DPPIV null mice have shown that these animals not
only display improved glucose tolerance (Marguet et al., 2000)
but also are resistant to the development of obesity induced by a
high fat diet (Conarello et al., 2003), which suggests that chronic
ablation of DPPIV activity confers metabolic beneﬁts that extend
beyond glucose homeostasis per se.
Previous studies have suggested that DPPIV inhibition may
have a beneﬁcial effect on blood pressure control as well
(Mistry et al., 2008; Okerson et al., 2011; Pacheco et al., 2011;
G. Giannocco et al. / European Journal of Pharmacology 698 (2013) 74–86 75Tanaka et al., 2011). The DPPIV inhibitor sitagliptin reduced both
systolic and diastolic blood pressure in nondiabetic patients with
mild to moderate hypertension (Mistry et al., 2008). Moreover, we
have previously shown that long-term inhibition of DPPIV in SHRs
beginning at the young, pre-hypertensive stage produces a
sustained reduction in blood pressure of approximately 15 mmHg
(Pacheco et al., 2011). To date, the mechanisms by which DPPIV
inhibition reduces blood pressure have only been partially
addressed (Girardi and Di Sole, 2012; Pacheco et al., 2011;
Tanaka et al., 2011).
On the basis of these observations, the present study was
undertaken to test the hypothesis that DPPIV inhibition may
upregulate GLUT4 translocation, protein levels and/or mRNA
expression in the skeletal and cardiac muscle of SHRs. The
possibility that the effect of DPPIV inhibition was, at least in part,
mediated by GLP-1 receptor stimulation and activation of the
cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA)
signal transduction pathway was also investigated.2. Material and methods
2.1. Materials
Reagents were purchased from Sigma Chemical Company (Saint
Louis, MO) unless stated otherwise. Januvia tablets (Merck &
Company, Inc.) containing 100 mg of sitagliptin monophosphate
were purchased from a local pharmacy. Rabbit polyclonal antibody
against GLUT4 was purchased from Millipore (Temecula, CA), the
monoclonal antibody against DPPIV, clone 5E8, and the rabbit
polyclonal antibody against the GLP-1 receptor were purchased
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA), and the
monoclonal antibody against actin JLA20 was from Calbiochem
(San Diego, CA). Anti-pSer/Thr PKA substrate antibody was pur-
chased from Cell Signaling Technology (Beverly, MA). Horseradish
peroxidase-conjugated goat anti-mouse and goat anti-rabbit sec-
ondary antibodies were purchased from Life Technologies Corpora-
tion (Carlsbad, CA).
2.2. Extraction of sitagliptin
Extraction of sitagliptin was performed as previously
described by Jackson and Mi (2008) with some modiﬁcations.
Given the fact that sitagliptin phosphate monohydrate is highly
water-soluble, four 100 mg Januvia tablets were added to 10 ml of
water and incubated in the refrigerator for 1 h to dissolve the
tablets. The suspension was vortexed and centrifuged at 2000 g
for 10 min to remove the majority of the excipients. The super-
natant was then diluted in water to a ﬁnal concentration of
20 mg/ml sitagliptin (determined based on the labeled amount of
sitagliptin in the tablet).
2.3. Animal procedures
Experimental procedures were performed in accordance with
the guidelines established by the Brazilian College for Animal
Experimentation (COBEA) and were approved by the institutional
animal care and use committee. Studies were conducted in male
SHRs at 5 (Y, young, n¼40) and 20 weeks (A, adult, n¼42) of age
that were randomly divided into two groups and treated twice a
day, by oral gavage, with sitagliptin (IDPPIV, 40 mg/day) or
vehicle (water) for a ten day period. Age-matched WKY rats
served as normotensive controls (n¼40). The 40 mg/day dosage
of sitagliptin was determined based on dose-response experi-
ments previously performed by Pacheco et al. (2011). The animals
were housed under constant temperature, humidity and lightcycle (12:12 h light:dark) conditions and had ad libitum access to
standard rat chow and tap water. At the end of the treatment
period and after a six hour fast, the animals were anesthetized
with an i.p. injection of sodium pentobarbital (50 mg/kg BW).
Blood samples were collected from the infraorbital plexus, and
the animals were subsequently killed by decapitation. The heart
and hindlimb skeletal muscles, including the gastrocnemius,
soleus, and extensor digitorum longus (EDL), were excised,
immediately frozen in liquid nitrogen, and stored at 80 1C for
subsequent protein and RNA extraction.
2.4. Blood pressure measurements
Systolic blood pressure was recorded in conscious restrained
animals by the tail-cuff method (BP-2000 Blood Pressure Analysis
System, Visitech Systems, Inc., Apex, NC) one day prior to the
administration of either sitagliptin or vehicle (Day 0) and after ten
days of treatment (Day 10). Prior to these measurements, the rats
were trained for two weeks with the blood pressure device to
allow them to become accustomed to the procedure.
2.5. Glucose tolerance test
Glucose tolerance tests were performed on both SHRs and
WKY rats on the eighth day of treatment with sitagliptin or the
vehicle. Animals were exposed to fasting conditions for six hours
(beginning approximately 8:00 AM), weighed, and injected intra-
peritoneally with a glucose solution (1.0 g/kg body weight). Blood
was withdrawn from tail veins of conscious animals at 0, 15, 30,
60, 90, and 120 min after glucose injection. Blood glucose con-
centration was immediately measured with the ACCU-CHEK s
Performa meter (Roche Diagnostics GmbH, Mannheim, Germany).
The area under the curve (AUC) was determined for quantiﬁcation
of the glucose tolerance test.
2.6. Measurements of plasma glucose, insulin, and DPPIV
Plasma samples were obtained by centrifugation of blood
samples at 4000 g for 10 min at 4 1C and were stored at 80 1C
until they were assayed for glucose and insulin levels and DPPIV
activity. Plasma glucose was measured by the hexokinase method
using a commercially available kit (Labtest, Lagoa Santa, MG,
Brazil). Plasma insulin concentration was measured with an ELISA
kit (Millipore) according to the manufacturer’s protocol. Plasma
DPPIV activity was measured colorimetrically using glycyl-prolyl-
para-nitroanilide as a chromogenic substrate as described
previously (Pacheco et al., 2011).
2.7. Determination of plasma concentrations of total and
active GLP-1
Blood from six rats per experimental group was withdrawn
from the retro-orbital plexus, immediately transferred into chilled
tubes containing 1 mg/ml EDTA and 10 mM of the DPPIV inhibitor
P32/98 (Enzo Life Sciences Inc., Farmingdale, NY) and centrifuged
at 4000 g and 4 1C for 10 min. Plasma samples were frozen and
stored at 80 1C. Samples were extracted using a solid phase
extraction C18-Ecolumn (Strata Phenomenex, Torrance, CA) in
accordance with the manufacturer’s instructions. The plasma
GLP-1 (total) concentration was determined by an enzyme-
linked immunosorbent assay (Millipore) according to the manu-
facturer’s instructions. Plasma levels of intact GLP-1 [7–36 amide]
were measured with an enzyme-linked immunosorbent assay
(Linco Research, St. Charles, MO), which uses an N-terminally
directed antibody that does not cross-react with the DPPIV
cleavage product GLP-1 [9–36 amide].
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from heart and skeletal muscles
The skeletal (soleus, EDL and gastrocnemius) and ventricular
muscles were excised from rats, minced with opposing razor
blades, and homogenized in a Polytron PT 2100 homogenizer
(Kinmatica, AG, Switzerland) in an ice cold buffer containing
1 mM EDTA, 250 mM sucrose, and 10 mM Tris, pH 7.5. The
homogenate was centrifuged at 760 g for 5 min at 4 1C. The
supernatant was removed and subjected to 60 min of centrifuga-
tion at 31,000 g and 4 1C to pellet the fraction enriched for the
plasma membrane. Next, the supernatant was subjected to
centrifugation for 60 min at 190,000 g and 41 C to pellet the
fraction enriched for microsomes. The protein concentra-
tion of both microsomal and plasma membrane fractions was
determined by the Lowry method (Lowry et al., 1951).
2.9. Evaluation of GLUT4 total and subcellular distribution
Total cellular GLUT4 protein expression was determined as the
sum of both the microsomal and plasma membrane subcellular
fractions (TOTAL). The percentage of GLUT4 in the plasma mem-
brane (PM) was calculated as (PM GLUT4/TOTAL GLUT4)100. The
amounts of TOTAL and plasma membrane GLUT4 are expressed as
percentages of the controls (normotensive WKY rats).
2.10. SDS-PAGE and immunoblotting
Equal amounts of protein or volume of plasma were resolved
by SDS-PAGE and analyzed by immunoblotting as previously
described (Crajoinas et al., 2010). The visualized bands were
digitized using an ImageScanner (GE HealthCare) and quantiﬁedFig. 1. Plasma dipeptidyl peptidase IV (DPPIV) activity and abundance in sitaglipt
activity was measured by a colorimetric method in young and adult SHRs treated with
per group, with the exception of the A-SHR and A-SHRþIDPPIV groups in which 15 ra
plasma of young and adult animals by immunoblotting. An equal volume of plasma (0.5
and incubated with a monoclonal antibody against DPPIV. Membranes were stained w
control. Values are the means7S.E.M. n¼6 animals/group ***Po0.001 vs. age-matchedusing the Scion Image Software package (Scion Corporation,
Frederick, MD).2.11. RNA isolation and quantitative real-time RT-PCR
Total RNA was isolated from skeletal and cardiac muscles with
TRIzol Reagent (Life Technologies Corporation, Carlsbad, CA). The
extracted RNA was quantiﬁed spectrophotometrically at 260 nm
and stored at 80 1C until further analysis. cDNA synthesis was
performed with the MML-V Reverse Transcriptase kit (Promega,
Madison, WC) according to the manufacturer’s recommended pro-
tocol. Quantitative real time PCR (RT-PCR) was carried out using the
QuantiTech SYBR green PCR kit (Qiagen, Valencia, CA) on an ABI
Prism 7500 Sequence Detection System (Applied Biosystems, Foster
City, CA). The following oligonucleotide primers were used to detect
GLUT4 (BC085757) and cyclophilin (XR 009383): GLUT4 forward:
50-CATTGCTTCTGGCTATCAC-30; GLUT4 reverse: 50-AACATGCTGGTT-
GAATAGTAG-30; cyclophilin forward: 50-GGATTCAT-GTGCCAGGG
TGG-30; and cyclophilin reverse: 50-CACATGCTTGCCATCCAGCC-30.
The ampliﬁcation conditions consisted of initial denaturation (95 1C
for 10 min) followed by 45 cycles of 95 1C for 20 s, 58 1C for 20 s, and
72 1C for 20 s. The comparative threshold (CT) cycle method was
used for data analysis.2.12. Indirect measurement of PKA activity
Equal amounts (15 mg) of plasma membrane protein isolated
from the heart and gastrocnemius muscles of SHR and WKY rats
were resolved by SDS-PAGE and analyzed by immunoblotting
using an antibody speciﬁc for phosphorylated PKA substrates
(Gronborg et al., 2002). The visualized bands were digitized usingin-treated and untreated SHRs and age-matched WKY rats. (A) Plasma DPPIV
sitagliptin or vehicle (water) for ten days and in age-matched WKY rats. n¼14 rats
ts were analyzed per group and (B) The abundance of DPPIV was evaluated in the
ml) from each animal was subjected to SDS-PAGE, transferred to a PVDF membrane
ith Ponceau S prior to antibody incubation and albumin was used as an internal
WKY rats.
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Image Software package (Scion Corporation, Frederick, MD).
2.13. Isolation and culture of rat cardiac myocytes
Cardiac myocytes were prepared by enzymatic disaggregation
as previously described (Barreto-Chaves et al., 2000). Brieﬂy, hearts
from neonatal (7–10 days old) SHRs were excised, and their
ventricles were minced and transferred to a sterile buffer. The
tissue was then subjected to multiple enzymatic digestions at 37 1C
using a mixture of collagenase and pancreatin. Five subsequent
digestions, each lasting for 20 min, were performed. The solution
obtained in each digestion was transferred to a tube containing
1 ml of newborn calf serum (NCS) and centrifuged. Each cell pellet
was resuspended in NCS. Dissociated cells were pooled. Cardiac
myocytes were isolated by layering the cell suspension onto a
discontinuous Percoll density gradient. After removing all traces of
Percoll, myocytes were cultured in DMEM containing 5% fetal
calf serum, 10% horse serum and 100 mM bromodeoxyuridine.
Myocytes were serum starved for 48 h prior to drug treatment.
2.14. Measurement of cyclic adenosine monophosphate (cAMP)
Cardiac myocytes were treated for 10 min with 1 mM
3-isobutyl-1-methylxanthine (IBMX) and subsequently incubated
for another 30 min with IBMX, IBMX with 50 nM GLP-1, IBMX
with 5 mM exendin-9 or IBMX with GLP-1 and exendin-4 . cAMP
levels were measured by an enzyme immunoassay (cAMP Direct
Biotrak EIA, GE HealthCare) according to the manufacturer’s
speciﬁcations.Fig. 2. Systolic blood pressure of young (Y-SHRs) and adult SHRs (A-SHRs)
before and after treatment with sitagliptin and of age-matched WKY rats.
Systolic blood pressure (SBP) was measured by the tail cuff method in young
(A) and adult (B) rats before and after sitagliptin (IDPPIV) or vehicle treatment.
WKY rats received no treatment. Values are the means7S.E.M. n¼14 rats per
group, with the exception of the A-SHR and A-SHRþ IDPPIV groups in which 15
rats were analyzed per group. nPo0.05 and nnnPo0.001 vs. age-matched WKY.2.15. Statistical analysis
Data are expressed as the means 7S.E.M. Comparisons among
groups were made by two-way analysis of variance (ANOVA),
except for assessing changes on blood pressure, in which repeated
measures analysis of variance (rANOVA) was applied. The Bonfer-
roni method was used to adjust the P value for multiple compar-
isons. The results were considered signiﬁcant when Po0.05.3. Results
3.1. Effect of sitagliptin on plasma DPPIV activity
Fig. 1 shows that DPPIV activity was signiﬁcantly increased in the
plasma of SHRs compared to WKY rats (Fig. 1A). Sitagliptin treatment
inhibited the activity of DPPIV in the plasma of both young and adult
SHRs to similar extents (8577%, Po0.001 and 8878%, Po0.001,
respectively). As shown in Fig. 1B, increased DPPIV activity in SHRs
compared to WKY rats was accompanied by a greater abundance of
the peptidase in the plasma of hypertensive animals. Surprisingly,
sitagliptin not only inhibited plasma DPPIV catalytic activity but also
decreased the circulating levels of the enzyme (Fig. 1B).
3.2. Effect of sitagliptin treatment on blood pressure
Fig. 2A shows the effect of sitagliptin treatment on the blood
pressure of young SHRs. Baseline systolic blood pressures were
similar between the two groups of young SHRs (Y-SHR and
Y-SHRþ IDPPIV) and were slightly but signiﬁcantly higher than in
the Y-WKY rat group. Treatment with sitagliptin for ten daysTable 1
Body weight (BW), food and water intake, plasma glucose and insulin concentrations
of young SHR treated with the DPPIV inhibitor sitagliptin (Y-SHRþIDPPIV) or water
(Y-SHR) and age-matched WKY (Y-WKY).
Y-WKY
(n¼14)
Y-SHR
(n¼14)
Y-SHRþIDPPIV
(n¼14)
BW at day 0 (g) 167715 12378a 12577a
BW at day 10 (g) 205715 15177a 15477a
% BW gain 22.771.8 22.771.3 23.271.7
Food intake (g/kg) 209717 206715 196711
Water intake (ml/kg) 15176 14576 14774
Glucose (mM) 5.9870.14 5.8170.24 5.6070.29
Insulin (ng/ml) 1.3170.26 1.4370.13 1.2370.17
All parameters are expressed as means7S.E.M.
a Po0.001 vs. Y-WKY. The number of animals in each experimental group is
shown in parenthesis.
Table 2
Body weight (BW), food and water intake, plasma glucose and insulin concentra-
tions of adult SHR treated with the DPPIV inhibitor sitagliptin (A-SHRþ IDPPIV) or
water (A-SHR) and age-matched WKY (A-WKY).
A-WKY
(n¼14)
A-SHR
(n¼15)
A-SHRþIDPPIV
(n¼15)
BW at day 0 41778 31977b 32378b
BW at day 10 42578 325710b 32878b
% BW gain 2.170.2 1.770.4 1.670.3
Food intake (g/kg) 131711 13079 12677
Water intake (ml/kg) 8574 8974 8773
Glucose (mM) 6.0670.20 6.1270.32 6.0170.34
Insulin (ng/ml) 1.4770.12 2.5870.27a 1.3670.20
All parameters are expressed as means7S.E.M.
a Po0.01.
b Po0.001 vs. A-WKY. The number of animals in each experimental group is
shown in parenthesis.
Fig. 3. Glucose Tolerance Test in sitagliptin-treated and untreated SHRs and age-matched WKY rats. Intraperitoneal glucose tolerance tests were performed following
a six-hour fast on young (A) and adult (B) SHRs treated with or without sitagliptin (IDPPIV) and age-matched WKY rats after an i.p. injection of D-glucose (1 g/kg of body
weight). Glucose was measured in blood samples from conscious rat tail veins at the indicated time intervals. (C) and (D) Glucose area under the curve (AUC) values are
presented as the means7S.E.M. n¼8 animals/group *Po0.05 and **Po0.01 vs. age-matched WKY rats. #Po0.05 and ###Po0.001 vs. age-matched SHR.
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group (11973 vs.13674 mmHg in the Y-SHR group; Po0.05). The
mean value of systolic blood pressure in the Y-SHRþ IDPPIV group
was not signiﬁcantly different from age-matched Y-WKY rats
(11973 vs. 10774mmHg, respectively; n.s.), whereas blood pres-
sure continued to increase in vehicle-treated Y-SHRs (Fig. 2A).
As shown in Fig. 2B, both groups of adult SHRs (A-SHR and
A-SHRþ IDPPIV) had markedly higher systolic blood pressures
than the normotensive control A-WKY rats both before and after
sitagliptin administration. Inhibition of plasma DPPIV in the adult
SHRs with established hypertension produced only a non-
statistically signiﬁcant trend towards reduced systolic blood
pressure compared to the vehicle-treated SHR control (19876
vs. 20577 mmHg, respectively; n.s.).
3.3. Effect of sitagliptin treatment on body weight and glucose
homeostasis
Body weight was greater in both young and adult WKY rats
than in age-matched SHRs before and after the ten-day experi-
mental period (Tables 1 and 2). Weight gain and food and
water consumption were unaltered by treatment with sitagliptin
(Tables 1 and 2). Plasma glucose and insulin were measured aftera six-hour fast (8:00–14:00 h). There were no signiﬁcant differ-
ences in blood glucose between SHRs and WKY rats at all ages
studied (Tables 1 and 2). Plasma insulin levels were not signiﬁ-
cantly different between the strains at young ages. Adult SHRs
displayed an enhanced plasma insulin concentration under fast-
ing normoglycemia. Inhibition of DPPIV by sitagliptin completely
restored plasma insulin levels in the A-SHRþ IDPPIV group.
Fig. 3 illustrates the plasma glucose response of Y-SHRs
(Fig. 3A and B) and A-SHRs (Fig. 3C and D) treated with and
without sitagliptin and of age-matched WKY rats at various times
after an i.p. injection of 1 mg/kg glucose. There were no signiﬁcant
differences in glucose response between Y-SHRs and Y-WKY rats
(Fig. 3A and B). In contrast, A-SHRs exhibited an increased glucose
response compared to A-WKY rats (Fig. 3C and D). Glucose AUC
responses after glucose load were signiﬁcantly reduced by
sitagliptin treatment in Y-SHRs and A-SHRs compared to the age-
matched vehicle-treated SHRs and normotensive controls (Fig. 3).
3.4. Effect of sitagliptin on GLUT4 protein expression and subcellular
localization in heart and skeletal muscle
The effects of sitagliptin on GLUT4 protein abundance and
subcellular localization were evaluated in various striated muscle
Fig. 4. GLUT4 protein expression in heart and skeletal muscle of sitagliptin-treated and untreated young SHRs and age-matched WKY rats. Graphical representation
of the total protein levels and plasma membrane expression of GLUT4 in (A) heart, (B) gastrocnemius, (C) soleus, and (D) extensor digitorum longus (EDL) muscle of young
SHRs treated with water (Y-SHR) or sitagliptin (Y-SHRþ IDPPIV) for ten days and age-matched WKY (Y-WKY) rats. Values are presented as the means7S.E.M. n¼6
animals/group *Po0.05 vs. Y-WKY.
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Fig. 4, the amount of GLUT4 in the plasma membrane fraction was
reduced in the heart cells of Y-SHRs compared to those of Y-WKY
rats (11.070.3%) (Fig. 4A) and in each of the skeletal muscles
examined, which included the slow-twitch oxidative soleus
(25.071.0%) (Fig. 4B), the fast-twitch glycolytic EDL
(12.070.2%) (Fig. 4C), and the fast-twitch glycolytic and oxi-
dative gastrocnemius (18.070.9%) (Fig. 4D). Reductions in the
GLUT4 plasma membrane levels in the heart, soleus and gastro-
cnemius were accompanied by a slight but signiﬁcant decrease in
total GLUT4 protein expression. The total GLUT4 protein levels in
these three types of muscle cells were normalized to the Y-SHRs
treated with sitagliptin for ten days (Y-SHRþ IDPPIV). There were
no statistically signiﬁcant differences between GLUT4 expression
in the plasma membrane of skeletal muscle cells from the
Y-SHRþ IDPPIV group and Y-WKY rats (Fig. 4B–D ). Interestingly,
DPPIV inhibition resulted in a signiﬁcant increase (þ20.070.5%)
in GLUT4 expression in the plasma membranes of heart muscle
cells from sitagliptin-treated Y-SHRs compared to normotensive
Y-WKY rats (Fig. 4A).
As shown in Fig. 5, reduction of GLUT4 expression in the
plasma membranes of heart and skeletal muscle cells was much
more pronounced in A-SHR vs. A-WKY rats than in Y-SHR vs.
Y-WKY rats. A-SHRs displayed decreased amounts of GLUT4 in the
plasma membrane fractions from the heart (32.071.0%)
(Fig. 5A), soleus (35.073.4%) (Fig. 5B), EDL (15.070.6%)
(Fig. 5C), and gastrocnemius (30.071.8%) (Fig. 5D) musclescompared to age-matched WKY rats. Decreased plasma mem-
brane GLUT4 expression was associated with lower GLUT4 levels
in the heart and in red muscles enriched with oxidative type I and
IIa myoﬁbers (soleus and gastrocnemius, respectively) (Fig.5).
Inhibition of DPPIV by sitagliptin increased GLUT4 plasma mem-
brane levels and total protein expression in the heart, soleus, and
gastrocnemius of in the A-SHRþ IDPPIV group to levels greater
than those found in the normotensive adult animals. Total GLUT-4
expression in the EDL was not altered in SHRs compared to WKY
rats and remained unchanged in sitagliptin-treated rats.
3.5. Effect of sitagliptin on GLUT4mRNA expression in heart
and skeletal muscle
The relative amounts of GLUT4mRNA in heart and skeletal
muscle cells derived from sitagliptin-treated and untreated SHRs
and WKY rats were determined by real time reverse transcription-
PCR (Figs. 6 and 7). As shown in Fig. 6, the GLUT4mRNA levels were
signiﬁcantly reduced in the heart (1871%), soleus (1771%),
and gastrocnemius (971%) muscles of Y-SHRs compared to
young normotensive rats (Y-WKY). There were no statistically
signiﬁcant differences in GLUT4 gene expression between young
SHRs treated with sitagliptin for ten days (Y-SHRþ IDPPIV) and
Y-WKY rats in all muscle tissues analyzed.
As depicted in Fig. 7, the expression of GLUT4 mRNA was
signiﬁcantly reduced in the heart (3871%), soleus (2271%)
and gastrocnemius (2271%) of A-SHRs compared to A-WKY rats.
Fig. 5. GLUT4 protein expression in heart and skeletal muscle of sitagliptin-treated and untreated adult SHRs and age-matched WKY rats. Graphical representation
of the total protein levels and plasma membrane expression of GLUT4 in (A) heart, (B) soleus, (C) extensor digitorum longus (EDL), and (D) gastrocnemius muscle of adult-
SHRs treated with water (A-SHR) or sitagliptin (A-SHRþIDPPIV) for ten days and age matched WKY (A-WKY) rats. Values are presented as the means7S.E.M. n¼6
animals/group *Po0.05 vs. A-WKY.
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treatment with sitagliptin increased GLUT4 mRNA expression
in the heart, soleus, and gastrocnemius of the A-SHRþ IDPPIV
group to levels greater than those of normotensive adult animals
(A-WKY).
3.6. Effect of sitagliptin treatment on the circulating levels of GLP-1
The effect of DPPIV inhibition on circulating levels of the
incretin hormone GLP-1 in young and adult SHRs is reported in
Fig. 8. Plasma levels of total GLP-1 (tGLP-1) did not vary
signiﬁcantly among young animals (Fig. 8A). On the other hand,
the levels of intact GLP-1, GLP-1[7–36], were 2.3 times greater in
sitagliptin-treated Y-SHRs than in Y-SHRs treated with water and
2.2 times greater than in Y-WKY rats (Fig. 8B). Additionally, there
was a non-signiﬁcant trend towards a decrease in plasma tGLP-1
in both the A-SHR and A-SHRþ IDPPIV groups compared to
A-WKY rats (Fig. 8A). Similar to the ﬁndings in young animals,
treatment with sitagliptin remarkably increased the plasma levels
of GLP-1[7–36] in the adult SHRs compared to both A-SHRs given
water and to A-WKY rats (Fig. 8B).
3.7. Effect of sitagliptin treatment on the levels of PKA-mediated
phosphorylation in the heart and gastrocnemius
The effect of DPPIV inhibition on PKA activity was estimated
by immunoblotting. As shown in Fig. 9A, sitagliptin treatmentincreased the levels of phosphorylated PKA substrates in the
plasma membrane of heart cells from both young and adult SHRs
compared to age-matched vehicle-treated SHR and WKY rats.
Conversely, DPPIV inhibition did not alter the levels of proteins
phosphorylated by PKA in the plasma membrane of gastrocne-
mius cells (Fig. 9B).
3.8. Direct effects of GLP-1 on SHR cardiomyocytes
As illustrated in Fig. 10A, the treatment of neonatal SHR
cardiac myocytes with 50 nM GLP-1 for 30 min increased the
intracellular levels of cAMP by 11477%. Additionally, as demon-
strated in Fig. 10B, incubation of SHR cardiomyocytes with GLP-1
for 24 h induced an increase in GLUT4 protein expression by
154713%. Both responses were blocked in the presence of the
GLP-1 receptor antagonist exendin-9 .4. Discussion
The present study demonstrates that inhibition of DPPIV by
sitagliptin upregulates GLUT4 translocation and expression at
both the protein and mRNA level in cardiac and oxidative
red muscles of young and adult spontaneously hypertensive
rats (SHRs). Interestingly, in adult SHRs, DPPIV inhibition upre-
gulates striated muscle GLUT4 expression to levels to a greater
extent than those found in age-matched normotensive animals.
Fig. 6. GLUT4-mRNA expression in heart and skeletal muscle of sitagliptin-treated and untreated young SHRs and age-matched WKY rats. Graphical representation
of the relative mRNA-GLUT4 expression levels in (A) heart, (B) soleus, (C) extensor digitorum longus (EDL), and (D) gastrocnemius muscle of young SHRs treated with
water (Y-SHR) or sitagliptin (Y-SHRþ IDPPIV) for ten days and age-matched WKY (Y-WKY) rats. GLUT4 mRNA expression was quantiﬁed by real time RT-PCR. Expression of
the GLUT4 transcript was normalized to cyclophilin mRNA. Values are presented as the means7S.E.M. n¼6 rats/group, *Po0.05 vs. Y-WKY.
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sitagliptin-treated SHRs exhibit an increased rate of plasma
glucose decay in following an i.p. injection of 1 mg/kg glucose
compared to age-matched WKY rats, suggesting that inhibition of
plasma DPPIV facilitates glucose uptake in the striated muscles
of SHRs.
Facilitated glucose uptake in muscle ﬁbers is mediated by
increases in the plasma membrane level of GLUT4 via insulin-
and/or muscle contraction-mediated GLUT4 translocation
(Lauritzen and Schertzer, 2010; Thorens et al., 1990). The present
study showed that at an age of 5–6 weeks, SHRs display lower
levels of GLUT4 in the plasma membrane of all types of striated
muscle cells analyzed (cardiac, oxidative and glycolytic myoﬁ-
bers) compared with age-matched WKY rats. Reduced plasmamembrane GLUT4 protein levels in heart and skeletal oxidative
muscles are accompanied by a decrease in total GLUT4 protein
and mRNA levels. Conversely, the expression level of GLUT4 was
not signiﬁcantly different between SHRs and WKY rats in EDL
muscles. Additionally, no change in GLUT4 expression was
observed in the EDL muscles of sitagliptin-treated SHRs. This
result may be related to the fact that stimulation of glucose
transport by insulin is greater in red muscles enriched with
oxidative type I and IIa myoﬁbers (soleus and gastrocnemius
muscles) than white muscles enriched with glycolytic type IIb
myoﬁbers (EDL) (James et al., 1985).
Glucose intolerance and/or hyperinsulinemia have been
reported to be present in many patients with essential hyperten-
sion. In accordance with previous studies (Buchanan et al., 1992;
Fig. 7. GLUT4 mRNA expression in heart and skeletal muscle of sitagliptin-treated and untreated adult SHRs and age-matched WKY rats. Graphical representation of
the relative GLUT4 mRNA expression levels in (A) heart, (B) soleus, (C) extensor digitorum longus (EDL), and (D) gastrocnemius muscle of adult-SHRs treated with water
(A-SHR) or sitagliptin (A-SHRþ IDPPIV) for ten days and age matched WKY (A-WKY) rats. GLUT4 mRNA expression was quantiﬁed by real time RT-PCR. Levels of GLUT4
mRNA were normalized to those of the internal control, cyclophilin mRNA. Values are presented as the means7S.E.M. n¼6 rats/group, *Po0.05; **Po0.01 and ***Po0.001
vs. A-WKY.
G. Giannocco et al. / European Journal of Pharmacology 698 (2013) 74–8682Chen et al., 1994; Lehnen et al., 2011), we found that adult SHRs
have normal blood glucose levels but an increased blood insulin
concentration. Additionally, we have found that a 10-day treat-
ment with sitagliptin normalizes plasma insulin levels in adult
hypertensive animals. Previously reported results demonstrated
that adult SHRs are hyperinsulinemic and normoglycemic
because of an enhanced sensitivity of their pancreatic beta cells
to glucose and that the SHR beta-cell hyperfunction is due to an
increase in the catalytic activity of glucokinase (Chen et al., 1994).
Interestingly, a correlation between DPPIV treatment, beta-cell
function and glucokinase activity has recently been reported by
Ding et al. (2001). Their study shows that the DPPIV substrate,GLP-1, stimulates post-translational activation of glucokinase and
that this might be one of the possible mechanisms by which GLP-1
exerts its insulinotropic effects on beta cells.
Several possible mechanisms may account for the events
triggered by DPPIV inhibition because DPPIV degrades a variety
of peptides known to modulate cardiovascular and/or metabolic
function (Brandt et al., 2006; Lambeir et al., 2003; Mentlein et al.,
1993a, 1993b; Palmieri and Ward, 1983; Shioda et al., 1998). The
results from this report demonstrate that sitagliptin-treated SHRs
have increased plasma concentrations of the active form of GLP-1
compared to SHRs treated with vehicle and WKY rats. The activity
of GLP-1 is transduced by a classical seven transmembrane
Fig. 8. Plasma GLP-1 levels of sitagliptin-treated and untreated young and adult SHR and age-matched WKY rats. Circulating levels of (A) total GLP-1 (GLP-1t) and (B)
active GLP-1(7–36) were measured by ELISA in young (Y) and adult (A) SHRs treated with sitagliptin (IDPPIV) or vehicle (water) for ten days and in age-matched WKY rats.
Values are presented as the means7S.E.M. n¼6 rats/group.**Po0.01 and ***Po0.001 vs. age-matched WKY.
Fig. 9. Levels of PKA-phosphorylated substrates in the plasma membranes of heart and gastrocnemius muscle cells isolated from sitagliptin-treated and untreated
young and adult SHRs and age-matched WKY rats. Phosphorylation levels of PKA substrates in the plasma membranes of (A) heart and (B) gastrocnemius muscle cells
from young (Y) and adult (A) SHRs treated with sitagliptin (IDPPIV) or vehicle (water) for ten and age-matched WKY rats were evaluated by immunoblotting using an
antibody that recognizes proteins containing a phospho-Ser/Thr residue with arginine residues at the 3 and 2 positions (i.e., the PKA consensus site). Top: Equal
amounts of protein (15 mg) from each animal were subjected to SDS-PAGE, transferred to a PVDF membrane and incubated with the anti-pSer/Thr antibody. Actin was used
as an internal control. Bottom: The sum total of all phospho-PKA proteins per lane was estimated by densitometry and normalized to actin. The arrows indicate the
proteins whose phosphorylation was increased by sitagliptin treatment. The combined data from 3 experiments are represented as columns in a bar graph. Values are
presented as the means7S.E.M. *Po0.05 and **Po0.01 vs. age-matched WKY.
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Fig. 10. Effect of GLP-1 receptor stimulation on intracellular cAMP and GLUT4 levels in cardiomyocytes isolated from neonatal SHRs. (A) Cells were incubated at
37 1C with culture medium containing 1 mM 3-isobutyl-1-methylxanthine (IBMX) (CTRL), IBMX and GLP-1 (50 nM), IBMX and exendin-9 (Ex-9) (5 mM), or a combination
of IBMX, GLP-1 and exendin-9 for 30 min prior to lysis. The generation of intracellular cAMP was measured by an enzyme immunoassay (cAMP Direct Biotrak EIA, GE
Healthcare) according to the manufacturer’s instructions. Each assay was performed in triplicate, and the mean value of four assays was calculated. (B) Top:
Cardiomyocytes were treated for 24 h with vehicle, 50 nM GLP-1, 5 mM Ex-9 or GLP-1 and Ex-9. Immunoblot analyses were performed using a polyclonal antibody against
GLUT4. Expression of GLUT4 was normalized to the actin control. Bottom: The levels of GLUT4 and actin were quantiﬁed by densitometry, and the combined data from
4 experiments are represented as columns in a bar graph ***Po0.001 vs. CTRL.
G. Giannocco et al. / European Journal of Pharmacology 698 (2013) 74–8684G protein-coupled receptor that is expressed in pancreatic islet
cells, as well as in the heart, kidneys, and vasculature, among
other tissues. It is worth mentioning that GLP-1 receptor mRNA
appears to be absent in rat skeletal muscles (Bullock BP, 1996).
Based on these observations, it can be postulated that DPPIV
inhibition-induced upregulation of GLUT4 may be due to a direct
effect on GLP-1 levels in the heart, may be due to an indirect
effect derived from the normalization of insulin levels and/or may
involve other peptidergic systems.
Ligand activation of the GLP-1 receptor stimulates adenylate
cyclase via Gas, which leads to an increase in intracellular cAMP
and activation of PKA. In the present study, we found that the
levels of PKA-phosphorylated proteins are increased in heart
muscle cell plasma membranes isolated from young and adult
sitagliptin-treated SHRs compared to SHRs treated with vehicle.
Conversely, no differences were found in PKA-mediated phosphor-
ylation of plasma membrane proteins isolated from gastrocnemius
muscle cells. These results suggest that increased GLP-1 bioactivity
may directly stimulate the GLP-1 receptor in the hearts of SHRs,
triggering a cascade of signaling events that culminates in
increased GLUT4 expression. Consistent with this hypothesis, our
results demonstrate that GLP-1 increases cAMP and GLUT4 expres-
sion in isolated cardiac myocytes via GLP-1 receptor stimulation.The observation that GLP-1 and GLP-1 receptor antagonists
modulate GLUT4 is not unprecedented. The GLP receptor agonist
exenatide improves glucose homeostasis and increases GLUT4
protein expression and glucose uptake in cardiac muscle from an
animal model of dilated cardiomyopathy (Vyas et al., 2011).
Moreover, Villanueva-Penacarrillo et al. (2001) have previously
shown that GLP-1 may upregulate GLUT4 expression at both the
transcriptional and translational levels in normal and diabetic
animals. Taken together, the results of our study and others
indicate that drugs that mimic GLP-1 or prolong its endogenous
half-life have the potential to upregulate GLUT4 function, trafﬁck-
ing to the plasma membrane and total expression.
In the current study, it appears that the beneﬁcial effects of
DPPIV inhibition on metabolic control in SHRs are not likely to be
associated with its effect on blood pressure because (1) DPPIV
inhibition signiﬁcantly lowers blood pressure only in young SHRs,
(2) despite normalizing blood insulin levels in adult SHRs,
sitagliptin does not reduce their blood pressure, and (3) DPPIV
inhibition increases GLUT4 expression in heart and skeletal
muscles of both young and adult SHRs. Indeed, the upregulation
of striated muscle GLUT4 expression in adult SHRs vs. age-
matched WKY rats is greater than the differences in expression
found among the younger groups. Of note, Katayama et al. (1994)
G. Giannocco et al. / European Journal of Pharmacology 698 (2013) 74–86 85have suggested that hyperinsulinemia does not seem to be
involved in the pathogenesis of hypertension in SHRs. This report
was supported by the observation that the anti-diabetic agent
troglitazone (CS-045) improved insulin resistance and decreased
systolic blood pressure in other models of hypertension, such as
obese Zucker rats (Yoshioka et al., 1993) and fructose-fed rats
(Lee et al., 1994); however, despite inducing signiﬁcant improve-
ments in glucose tolerance in SHRs, troglitazone failed to reduce
blood pressure in these animals (Katayama et al., 1994).
An intriguing novel ﬁnding of this study is that treatment with
sitagliptin not only decreases plasma DPPIV activity but also
dramatically reduces the circulating levels of the peptidase in
SHRs. Additionally, both young and adult hypertensive animals
display higher plasma activity and abundance of the peptidase
compared to age-matched WKY rats. The origin of plasma DPPIV
has been attributed to its proteolytic cleavage from the surface of
peripheral lymphocytes, especially T-lymphocytes, through an as
yet unidentiﬁed sheddase (i.e., an enzyme that sheds the extra-
cellular portion of transmembrane proteins) (Lambeir et al.,
2003). Nonetheless, it is tempting to speculate that this unknown
sheddase might be upregulated in essential hypertension and that
inhibitors of DPPIV may downregulate the activity of this pro-
tease. Important areas for future work will be to identify the
sheddase that cleaves DPPIV from the cell surface and to under-
stand how this protease is regulated under physiological and
pathophysiological conditions.
In summary, the results of the present study demonstrate that
the DPPIV inhibitor sitagliptin upregulates GLUT4 translocation
and expression in skeletal and cardiac muscles of SHRs. The
underlying mechanism for sitagliptin-induced upregulation of
GLUT4 may be, at least partially, attributed to a corresponding
increase in plasma GLP-1[7–36] levels. Furthermore, our study
sheds light upon new mechanisms by which DPPIV inhibitors
improve glycemic control.Acknowledgments
This work was supported by the Fundac- ~ao de Amparo a
Pesquisa do Estado de S~ao Paulo (FAPESP) [Grant 2007/52945-8]
and by the Conselho Nacional de Desenvolvimento Cientı´ﬁco e
Tecnolo´gico (CNPq) [Grant 480775/2007-9].References
Ahren, B., 2003. Gut peptides and type 2 diabetes mellitus treatment. Curr. Diab.
Rep. 3, 365–372.
Barreto-Chaves, M.L., Heimann, A., Krieger, J.E., 2000. Stimulatory effect of
dexamethasone on angiotensin-converting enzyme in neonatal rat cardiac
myocytes. Braz. J. Med. Biol. Res. 33, 661–664.
Brandt, I., Lambeir, A.M., Ketelslegers, J.M., Vanderheyden, M., Scharpe, S., De
Meester, I., 2006. Dipeptidyl-peptidase IV converts intact B-type natriuretic
peptide into its des-SerPro form. Clin. Chem. 52, 82–87.
Buchanan, T.A., Youn, J.H., Campese, V.M., Sipos, G.F., 1992. Enhanced glucose
tolerance in spontaneously hypertensive rats. Pancreatic beta-cell hyperfunc-
tion with normal insulin sensitivity. Diabetes 41, 872–878.
Campbell, I.W., Dominiczak, A.F., Livingstone, C., Gould, G.W., 1995. Analysis of the
glucose transporter compliment of metabolically important tissues from the
Milan hypertensive rat. Biochem. Biophys. Res. Commun. 211, 780–791.
Chen, C., Hosokawa, H., Bumbalo, L.M., Leahy, J.L., 1994. Mechanism of compensa-
tory hyperinsulinemia in normoglycemic insulin-resistant spontaneously
hypertensive rats. Augmented enzymatic activity of glucokinase in beta-
cells. J. Clin. Invest. 94, 399–404.
Chiappe De Cingolani, G.E., Caldiz, C.I., 2004. Insulin resistance and GLUT-4 glucose
transporter in adipocytes from hypertensive rats. Metabolism 53, 382–387.
Conarello, S.L., Li, Z., Ronan, J., Roy, R.S., Zhu, L., Jiang, G., Liu, F., Woods, J., Zycband,
E., Moller, D.E., Thornberry, N.A., Zhang, B.B., 2003. Mice lacking dipeptidyl
peptidase IV are protected against obesity and insulin resistance. Proc. Nat.
Acad. Sci. U.S.A. 100, 6825–6830.
Crajoinas, R.O., Lessa, L.M., Carraro-Lacroix, L.R., Davel, A.P., Pacheco, B.P., Rossoni,
L.V., Malnic, G., Girardi, A.C., 2010. Posttranslational mechanisms associatedwith reduced NHE3 activity in adult vs. young prehypertensive SHR. Am. J.
Physiol. Renal. Physiol. 299, F872–881.
Ding, S.Y., Nkobena, A., Kraft, C.A., Markwardt, M.L., Rizzo, M.A., 2001. Glucagon-
like peptide 1 stimulates post-translational activation of glucokinase in
pancreatic beta cells. J. Biol. Chem. 286, 16768–16774.
Drucker, D.J., 2003. Therapeutic potential of dipeptidyl peptidase IV inhibitors for
the treatment of type 2 diabetes. Expert Opin. Investig. Drugs 12, 87–100.
Drucker, D.J., Nauck, M.A., 2006. The incretin system: glucagon-like peptide-1
receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Lancet 368, 1696–1705.
Girardi, A.C., Di Sole, F., 2012. Deciphering the mechanisms of the Naþ/Hþ
exchanger-3 regulation in organ dysfunction. Am. J. Physiol. Cell. Physiol. 302,
C1569–1587.
Gronborg, M., Kristiansen, T.Z., Stensballe, A., Andersen, J.S., Ohara, O., Mann, M.,
Jensen, O.N., Pandey, A., 2002. A mass spectrometry-based proteomic
approach for identiﬁcation of serine/threonine-phosphorylated proteins by
enrichment with phospho-speciﬁc antibodies: identiﬁcation of a novel pro-
tein, Frigg, as a protein kinase A substrate. Mol. Cell. Proteomics 1, 517–527.
Holst, J.J., 2007. The physiology of glucagon-like peptide 1. Physiol. Rev. 87,
1409–1439.
Jackson, E.K., Mi, Z., 2008. Sitagliptin augments sympathetic enhancement of the
renovascular effects of angiotensin II in genetic hypertension. Hypertension
51, 1637–1642.
James, D.E., Brown, R., Navarro, J., Pilch, P.F., 1988. Insulin-regulatable tissues
express a unique insulin-sensitive glucose transport protein. Nature 333,
183–185.
James, D.E., Jenkins, A.B., Kraegen, E.W., 1985. Heterogeneity of insulin action in
individual muscles in vivo: euglycemic clamp studies in rats. Am. J. Physiol.
248, E567–574.
Katayama, S., Abe, M., Kashiwabara, H., Kosegawa, I., Ishii, J., 1994. Evidence
against a role of insulin in hypertension in spontaneously hypertensive rats.
CS-045 does not lower blood pressure despite improvement of insulin
resistance. Hypertension 23, 1071–1074.
Katayama, S., Inaba, M., Maruno, Y., Morita, T., Awata, T., Oka, Y., 1997. Glucose
intolerance in spontaneously hypertensive and Wistar-Kyoto rats: enhanced
gene expression and synthesis of skeletal muscle glucose transporter 4.
Hypertens. Res. 20, 279–286.
Lambeir, A.M., Durinx, C., Scharpe, S., De Meester, I., 2003. Dipeptidyl-peptidase IV
from bench to bedside: an update on structural properties, functions, and
clinical aspects of the enzyme DPP IV. Crit. Rev. Clin. Lab. Sci. 40, 209–294.
Lauritzen, H.P., Schertzer, J.D., 2010. Measuring GLUT4 translocation in mature
muscle ﬁbers. Am. J. Physiol. Endocrinol. Metab. 299, E169–179.
Lee, M.K., Miles, P.D., Khoursheed, M., Gao, K.M., Moossa, A.R., Olefsky, J.M., 1994.
Metabolic effects of troglitazone on fructose-induced insulin resistance in the
rat. Diabetes 43, 1435–1439.
Lehnen, A.M., Leguisamo, N.M., Pinto, G.H., Markoski, M., De Angelis, K., Machado,
U.F., Schaan, B., 2011. Exercise-stimulated GLUT4 expression is similar in
normotensive and hypertensive rats. Horm. Metab. Res. 43, 231–235.
Lowry, O.H., Rosebrough, N.J., Farr, A.L., Randall, R.J., 1951. Protein measurement
with the Folin phenol reagent. J. Biol. Chem. 193, 265–275.
Marguet, D., Baggio, L., Kobayashi, T., Bernard, A.M., Pierres, M., Nielsen, P.F., Ribel,
U., Watanabe, T., Drucker, D.J., Wagtmann, N., 2000. Enhanced insulin secre-
tion and improved glucose tolerance in mice lacking CD26. Proc. Nat. Acad. Sci.
U.S.A. 97, 6874–6879.
Mentlein, R., Dahms, P., Grandt, D., Kruger, R., 1993a. Proteolytic processing of
neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul. Pept. 49,
133–144.
Mentlein, R., Gallwitz, B., Schmidt, W.E., 1993b. Dipeptidyl-peptidase IV hydro-
lyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36) amide,
peptide histidine methionine and is responsible for their degradation in
human serum. Eur. J. Biochem. 214, 829–835.
Mistry, G.C., Maes, A.L., Lasseter, K.C., Davies, M.J., Gottesdiener, K.M., Wagner, J.A.,
Herman, G.A., 2008. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on
blood pressure in nondiabetic patients with mild to moderate hypertension.
J. Clin. Pharmacol. 48, 592–598.
Okerson, T., Yan, P., Stonehouse, A., Brodows, R., 2011. Effects of exenatide on
systolic blood pressure in subjects with type 2 diabetes. Am. J. Hypertens. 23,
334–339.
Pacheco, B.P., Crajoinas, R.O., Couto, G.K., Davel, A.P., Lessa, L.M., Rossoni, L.V.,
Girardi, A.C., 2011. Dipeptidyl peptidase IV inhibition attenuates blood
pressure rising in young spontaneously hypertensive rats. J. Hypertens. 29,
520–528.
Palmieri, F.E., Ward, P.E., 1983. Mesentery vascular metabolism of substance P.
Biochim. Biophys. Acta 755, 522–525.
Paternostro, G., Clarke, K., Heath, J., Seymour, A.M., Radda, G.K., 1995. Decreased
GLUT-4 mRNA content and insulin-sensitive deoxyglucose uptake show
insulin resistance in the hypertensive rat heart. Cardiovasc. Res. 30, 205–211.
Reaven, G.M., Chang, H., Hoffman, B.B., Azhar, S., 1989. Resistance to insulin-
stimulated glucose uptake in adipocytes isolated from spontaneously hyper-
tensive rats. Diabetes 38, 1155–1160.
Shioda, T., Kato, H., Ohnishi, Y., Tashiro, K., Ikegawa, M., Nakayama, E.E., Hu, H.,
Kato, A., Sakai, Y., Liu, H., Honjo, T., Nomoto, A., Iwamoto, A., Morimoto, C.,
Nagai, Y., 1998. Anti-HIV-1 and chemotactic activities of human stromal cell-
derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26/
dipeptidyl peptidase IV-mediated cleavage. Proc. Nat. Acad. Sci. U.S.A. 95,
6331–6336.
G. Giannocco et al. / European Journal of Pharmacology 698 (2013) 74–8686Tanaka, T., Nangaku, M., Nishiyama, A., 2011. The role of incretins in salt-sensitive
hypertension: the potential use of dipeptidyl peptidase-IV inhibitors. Curr.
Opin. Nephrol. Hypertens. 20, 476–481.
Thorens, B., Charron, M.J., Lodish, H.F., 1990. Molecular physiology of glucose
transporters. Diabetes Care. 13, 209–218.
Villanueva-Penacarrillo, M.L., Puente, J., Redondo, A., Clemente, F., Valverde, I.,
2001. Effect of GLP-1 treatment on GLUT2 and GLUT4 expression in type 1 and
type 2 rat diabetic models. Endocrine 15, 241–248.Vyas, A.K., Yang, K.C., Woo, D., Tzekov, A., Kovacs, A., Jay, P.Y., Hruz, P.W., 2011.
Exenatide improves glucose homeostasis and prolongs survival in a murine
model of dilated cardiomyopathy. PLoS One 6, e17178.
Yoshioka, S., Nishino, H., Shiraki, T., Ikeda, K., Koike, H., Okuno, A., Wada, M.,
Fujiwara, T., Horikoshi, H., 1993. Antihypertensive effects of CS-045 treatment
in obese Zucker rats. Metabolism 42, 75–80.
